Clinical Trial Update: Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sodium benzoate and/or N-acetylcysteine added to treatment as usual in early schizophrenia spectrum disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia
• Schizophreniform Disorders

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)
• Sodium benzoate (sodium benzoate)

Snippet

Sponsor: Pakistan Institute of Living and Learning | Conditions: Schizophrenia, Schizophreniform Disorders | Phase 2 | Status: COMPLETED